Parasitic Organism Or Component Thereof Or Substance Produced By Said Parasitic Organism (e.g., Schistosoma, Dirofilaria, Trichinella, Fasciola, Ancylostoma, Ascaris, Etc.) Patents (Class 424/265.1)
Abstract: Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a yeast vehicle and an antigen that is not complexed to the yeast vehicle is disclosed.
Type:
Application
Filed:
August 12, 2009
Publication date:
December 10, 2009
Applicants:
GLOBELMMUNE, INC., THE REGENTS OF THE UNIVERSITY OF COLORADO
Inventors:
RICHARD C. DUKE, DONALD BELLGRAU, ALEX FRANZUSOFF, CARA C. WILSON
Abstract: The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein immunogen. The above VLP and a protein or a protein extract from a viral, bacterial or parasital pathogen may be used as a vaccine.
Abstract: A method of detecting osteoporosis in a mammalian is disclosed herein which includes: a) obtaining a sample of a bone related tissue or cells; and b) measuring the concentration of at least a marker which is either bacteria, bacteria produced factors, or HSPs. The method may further include comparing the concentration with concentrations from the same individual over a period of time or against a standard concentration. The marker may be a bacteria, a chaperone molecule, or a bacteria produced. Also provided herein is a method of treating or preventing osteoporosis caused by a bone disease which includes administering to a mammalian subject a therapeutically effective amount of a formulation which is either an HSP antigenic formulation or a bacterial antigenic formulation. The osteoporosis can be caused by a bone disease induced by bone infectious agents such as viruses, bacteria, fungi, protozoa and parasites.
Type:
Application
Filed:
May 18, 2009
Publication date:
November 12, 2009
Applicant:
DEPUY MITEK, INC.
Inventors:
Kai-Uwe Lewandrowski, Debra J. Trantolo
Abstract: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.
Type:
Application
Filed:
March 30, 2009
Publication date:
October 8, 2009
Applicant:
ID BIOMEDICAL CORPORATION OF QUEBEC
Inventors:
David S. Burt, George H. Lowell, Gregory L. White, David Jones, Clement Rioux
Abstract: Compositions and methods for the detection of Taenia solium and the diagnosis of T. solium infection are described. The nucleotide and amino acid sequences of the antigenic T. solium polypeptides gp50a, gp50b and gp50c are provided. The compositions contain synthetic antigenic polypeptides of larval origin prepared using the sequences described herein. Probes and primers for the detection or amplification of T. solium nucleic acid molecules are also described. The polypeptides can be administered to a human or animal to protect against T. solium infection. In addition, the polypeptides are useful as research tools for studying T. solium and as reagents in assays for the detection of T. solium antibodies in a biological sample. The methods are sensitive and specific assays that utilize the stable recombinant or synthetic antigenic polypeptides or nucleic acid molecules encoding the larval polypeptides.
Type:
Grant
Filed:
August 21, 2006
Date of Patent:
September 29, 2009
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
Inventors:
Victor C. W. Tsang, Ryan M. Greene, Patricia P. Wilkins, Kathy Hancock
Abstract: The membrane scaffold proteins (MSP) of the present invention assemble with hydrophobic or partially hydrophobic proteins to form soluble nanoscale particles which preserve native structure and function; they are improved over liposomes and detergent micelles, in terms of stability and preservation of biological activity and native conformation. In the presence of phospholipid, MSPs form nanoscopic phospholipid bilayer disks, with the MSP stabilizing the particle at the perimeter of the bilayer domain. The particle bilayer structure allows manipulation of incorporated proteins in solution or on solid supports, including for use with such surface-sensitive techniques as scanning probe microscopy or surface plasmon resonance. The nanoscale particles, which are robust in terms of integrity and maintenance of biological activity of incorporated proteins, facilitate pharmaceutical and biological research, structure/function correlations, structure determinations, bioseparations, and drug discovery.
Type:
Grant
Filed:
January 11, 2005
Date of Patent:
September 22, 2009
Assignee:
The Board of Trustees of the University of Illinois, a body corporate and politic of the State of Illinois
Inventors:
Stephen G. Sligar, Timothy H. Bayburt, Mary A. Schuler, Natanya R. Civjan, Ylena V. Grinkova, Ilia G. Denisov, Stephen James Grimme
Abstract: The present invention relates to dermal vaccine formulations, designed for targeted delivery of an immunogenic composition to a dermal compartment of skin including the intradermal and epidermal compartments. The dermal vaccine formulations of the invention comprise an antigenic or immunogenic agent, and at least one molecule, e.g., a chemical agent, which enhances the presentation and/or availability of the antigenic or immunogenic agent to the immune cells of the intradermal compartment or epidermal compartment resulting in an enhanced immune response. The dermal vaccine formulations of the invention have enhanced efficacy as the antigenic or immunogenic agent is delivered to the intradermal compartment or epidermal compartment with enhanced presentation and/or availability to the immune cells that reside therein.
Type:
Grant
Filed:
December 6, 2004
Date of Patent:
September 15, 2009
Assignee:
Becton, Dickinson and Company
Inventors:
Robert L. Campbell, Kevin G. Dolan, Wendy D. Woodley
Abstract: Vaccine containing a first vaccine, adjuvated with an oil-in-water emulsion comprising 5% squalene, 0.5% polysorbate 80 and 0.5% sorbitan trioleate in aqueous citrate buffer pH 6.5, and a nonadjuvated second vaccine as combination partners for the simultaneous, separate or phased application for immunization against viral, bacterial or parasitic infectious diseases.
Abstract: The present invention relates generally to a method of eliciting or otherwise inducing an effective immune response to a micro-organism and compositions for use therein. More particularly, the present invention relates to a method of inducing an immune response to a parasite utilising an immunogenic composition comprising a glycosylphosphatidylinositol (referred to herein as “GPI”) inositolglycan domain or its derivatives. Even more particularly, the present invention contemplates an immunogenic composition comprising the Plasmodium falciparum GPI inositolglycan domain or its derivatives. The present invention is useful, inter alia, as a prophylactic and/or therapeutic treatment for disease conditions such as, for example, infection by parasites and in particular infection by Plasmodium species.
Type:
Grant
Filed:
September 14, 1999
Date of Patent:
August 18, 2009
Assignee:
The Walter and Eliza Hall Institute of Medical Research
Abstract: The invention relates to an anti-inflammatory oligopeptide which can be obtained from the microorganism Entamoeba histolytica or synthesized by known methods. The oligopeptides are useful in treating inflammatory diseases when formulated in pharmaceutical compositions for administration to patients.
Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.
Abstract: Immunogenic compositions are described herein which comprise microparticles that further comprise a biodegradable polymer. The microparticle compositions also comprise a cationic polysaccharide and an immunological species selected from an antigen, an immunological adjuvant and a combination thereof. Also described are methods of making such compositions and methods of administering such compositions. Methods of modulating the release rate of immunological species from microparticles are also described. These methods comprise varying the ratio of the cationic polysaccharide relative to the biodegradable polymer within the microparticles.
Type:
Application
Filed:
February 24, 2007
Publication date:
July 2, 2009
Inventors:
Derek O' Hagan, Manmohan Singh, Janet Wendorf, Jina Kazzaz, Padma Malyala
Abstract: The subject invention provides polynucleotide sequences, designated BIVM, and transcriptional/translational products obtained from the polynucleotide sequences of the invention. The subject invention also provides polynucleotide and polypeptide sequences provided by SEQ ID NOs:1-28. Also provided are methods of detecting the presence of BIVM nucleic acids or polypeptides in samples suspected of containing BIVM genes, BIVM transcriptional products, or BIVM translational products. These methods are also useful for the detection of BIVM orthologs. Other embodiments provide polypeptide and/or nucleic acid vaccines for the induction of an immune response to in an individual. Kits for detecting the presence of BIVM genes, orthologs thereof, BIVM polypeptides, or BIVM transcriptional products are also provided.
Type:
Grant
Filed:
May 2, 2006
Date of Patent:
June 30, 2009
Assignee:
University of South Florida
Inventors:
Gary W. Litman, Noel A. Hawke, Jeffrey A. Yoder, Donna D. Eason
Abstract: The present invention provides a vaccine composition including a nucleic acid that encodes an amoeba-derived antigen (or a peptide molecule encoded thereby), or fragments or variants thereof. The present invention also provides for the use of such vaccine compositions in eliciting an immune response and/or protective immunity in a host against amoebic infection and screening a sample for the presence of amoebae.
Type:
Application
Filed:
October 1, 2007
Publication date:
June 25, 2009
Applicants:
Commonwealth Scientific and Industrial Research Organization, Cooperative Research Centre for Sustainable Aquaculture of Finfish (Aquafin CRC)
Inventors:
Matt Cook, Nick Elliot, Jawahar Patil, Barbara Nowak, Michael Attard, Phil Crosbie, Richard Morrison, Giles Campbell, Bronwyn Holmes, Christopher Prideaux
Abstract: The present invention relates to methods of treating or preventing a disease, disorder or condition associated with a viral infection using a dosing and resting regimen for administering a pharmaceutical composition that provides ARP.
Abstract: The present invention relates to an adjuvant comprising a lipopeptide and poly I:C. When the adjuvant of the present invention is used, the level of antigen specific antibody induction is synergistically increased and Th1 type immune response is also induced. Therefore, the adjuvant of the present invention can be very effectively used as an adjuvant in the formulation of preventive and therapeutic vaccines for viral or parasitic infection and cancer.
Type:
Application
Filed:
December 5, 2008
Publication date:
June 18, 2009
Applicant:
DOBEEL CORPORATION
Inventors:
Hong Mo Moon, Byung Cheol Ahn, Jung-Sun Yum
Abstract: A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor Receptor Ligand is provided. M-CSF receptor ligands induce DCs to differentiate into subtypes, for example plasmacytoid DCs and conventional DCs. Induction with an M-CSF receptor ligand can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF receptor ligand-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF receptor ligands can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.
Abstract: Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.
Type:
Grant
Filed:
December 9, 2005
Date of Patent:
June 2, 2009
Assignee:
Applied NanoSystems, B.V.
Inventors:
Cornelis Johannes Leenhouts, Ranjan Ramasamy, Anton Steen, Jan Kok, Girbe Buist, Oscar Paul Kuipers
Abstract: The present invention relates to novel compositions comprising copepods, such as marine Calanus species, process for the production thereof and use of said compositions in the prevention and/or treatment of ectoparasite infestations in animals. Further the invention relates to methods for prevention and/or treatment of ectoparasite infestations in aquatic animals, particularly fish.
Abstract: The primary objective of the present invention is the development of new mutant forms of the Sm14 protein, for producing a greater production volume. The recombinant proteins here obtained were capable of providing protection against schistosome and fasciola infection. The level of protection of Sm14 recombinant proteins obtained in the present invention was similar to that reached in the parasite saline extract. The mutant proteins of the present invention have reached approximately 100% of renaturation after the heating at 80° C., different from wild forms of the Sm14 protein. Moreover, after storage for 2 months at 4° C., mutant proteins have shown smaller ?-structure loss than wild forms that have shown formation with random structure, as demonstrated by the circular dichroism analysis, indicating the success of mutations.
Type:
Grant
Filed:
January 30, 2004
Date of Patent:
May 19, 2009
Assignee:
Fundacao Oswaldo Cruz - Fiocruz
Inventors:
Miriam Tendler, Naftale Katz, Andrew J. Simpson, Isaias Raw, Paulo Lee Ho, Celso Raul Romero Ramos
Abstract: The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor.
Type:
Application
Filed:
August 8, 2006
Publication date:
May 14, 2009
Applicant:
Avir Green Hills Biotechnology Research Development Trade AG
Inventors:
Monika Sachet, Michael Bergmann, Thomas Muster, Andrej Egorov
Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
Type:
Grant
Filed:
August 25, 2004
Date of Patent:
April 14, 2009
Assignee:
Idera Pharmaceuticals, Inc.
Inventors:
Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
Abstract: The invention relates to an anti-inflammatory oligopeptides which contain the terminal pharmacophore Cys-Asn-Ser which is capable of inhibiting the NF-?? signaling pathway. The oligopeptides are useful in stimulating the in vivo production of IL-10, and for treating inflammatory diseases and scarring when formulated in pharmaceutical compositions for administration to patients.
Abstract: The instant invention relates to methods for treating a subject suffering from or susceptible to an autoimmune disease or disorder, or a disease or disorder having an autoimmune component, comprising administering to the subject an effective amount of cyclophilin or a biologically active fragment thereof.
Type:
Grant
Filed:
July 8, 2005
Date of Patent:
March 31, 2009
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors:
Julio Aliberti, John Andersen, Hana Golding, Alan Sher
Abstract: The present invention provides vaccines and methods for making the vaccines that actively or passively protect an equid or other animal against Sarcocystis neurona. In particular, the present invention provides vaccines that provide active immunity which comprise a polypeptide or DNA vaccine that contains or expresses at least one epitope of an antigen that has an amino acid sequence substantially similar to a unique 16 (±4) kDa antigen and/or 30 (±4) kDa antigen of Sarcocystis neurona. The present invention further provides a vaccine that provides passive immunity to Sarcocystis neurona comprising polyclonal or monoclonal antibodies against at least one epitope of an antigen substantially similar to a unique 16 (±4) kDa antigen and/or 30 (±4) kDa antigen of Sarcocystis neurona.
Type:
Grant
Filed:
September 26, 2000
Date of Patent:
March 31, 2009
Assignee:
Board of Trustees of Michigan State University
Inventors:
Linda S. Mansfield, Mary G. Rossano, Alice J. Murphy, Ruth A. Vrable
Abstract: The invention relates to a composition for storage and development of eggs from helminthic parasites, where the composition further comprises a liquid carrier having a pH value of below 7 at a temperature of from 1° C. to ambient temperature. The liquid carrier can be sulphuric acid, H2SO4 with a pH in the range of from O to 2, and antibiotics can be added. The invention further relates to a method for treating, ameliorating, prophylactic or curative, an autoimmune or allergic disease in an individual, animal or man, using eggs being separated from the composition. The present invention also relates to methods for isolation, embryonation and preservation of eggs of helminthic parasite, and to a method for producing a pharmaceutical composition comprising a helminthic parasite preparation. The helminthic parasite eggs may be from the pig whipworm; Trichuris suis ova (TSO).
Type:
Application
Filed:
December 29, 2006
Publication date:
March 19, 2009
Inventors:
Christian Mollin Outzen Kapel, Allan Roepstorff, Stig Milan Thamsborg
Abstract: The invention concerns novel Plasmodium falciparum antigens and their vaccine and diagnostic applications. More particularly, the invention concerns immunogenic polynucleotide and polypeptide molecules, compositions comprising them, and methods for diagnosis and vaccination of malaria.
Abstract: A vaccine composition is provided which comprises inverted microsomes or fragments thereof from an animal cell in association with an externally disposed peptide antigen and a protein of the MHC.
Abstract: This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 ?m and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation.
Type:
Application
Filed:
March 15, 2007
Publication date:
February 12, 2009
Applicant:
UNIVERSITEIT GENT
Inventors:
Jean Paul Remon, Chris Vervaet, Evy Corbanie
Abstract: A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating toxin, optionally comprising one or more amino acid additions, deletions or substitutions.
Abstract: The invention concerns the use of at least one: a) a GILZ protein, a functional fragment of at least 5 consecutive amino acids of said protein, a GILZ modulator, or a recombinant vector expressing same, isolated or expressed in modified dendritic cells, and b) an antigen of interest and/or a molecule allowing targeting and/or passage of the plasmic membrane of dendritic cells, to prepare a medicine for preventing and/or treating autoimmune, inflammatory diseases, allergies, graft rejection and graft-versus-host disease, cancers and pathogenic micro-organism infections.
Type:
Application
Filed:
September 9, 2005
Publication date:
January 29, 2009
Applicant:
Assistance Publique-Hopitaux De Paris
Inventors:
Dominique Emilie, Nicolas Cohen, Francois Lemoine
Abstract: The present invention relates to nucleic acid sequences encoding novel Babesia canis associated proteins and to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Furthermore, the invention relates to host cells comprising such nucleic acid sequences, cDNA fragments, recombinant DNA molecules and live recombinant carriers. Also, the invention relates to proteins encoded by these nucleotide sequences, to vaccines for combating Babesia canis infections comprising these proteins or genetic material encoding these proteins and methods for the preparation of vaccines. Another embodiment of the invention relates to these Babesia canis associated proteins for use in vaccines and to the use of the Babesia canis associated proteins in the manufacture of vaccines.
Type:
Grant
Filed:
October 11, 2005
Date of Patent:
January 20, 2009
Assignee:
Intervet International B.V.
Inventors:
Theodorus Petrus Maria Schetters, Bernard Pierre Dominique Carcy, Pascal Robert Drakulovski, Andre Francois Gorenflot
Abstract: Maternal adaptive immunity conveys temporary humoral immune protection to neonates. The disclosure demonstrates the influence of the in utero environment on adult atherosclerosis and provides evidence for persistent effects of maternal immunization on adult immune responses. The disclosure provides methods and compositions useful for immunization and more particularly for actively modulating the fetal programming of the immune system for the purpose of preventing or treating immune-modulated diseases. The disclosure also provides interventions to protect offspring and immunized subjects against insulin resistance.
Type:
Application
Filed:
June 13, 2008
Publication date:
December 18, 2008
Applicant:
The Regents of the University of California
Abstract: A Neospora caninum vaccine comprising tissue culture grown Neospora and methods of making and using said vaccines. Neospora caninum vaccines described include those containing whole Neospora tachyzoites, extracts of Neospora tachyzoites and protective antigen subunits of Neospora tachyzoites. The vaccines of this invention may be in a liquid or lyophilized form.
Abstract: The present invention provides an isolated nucleic acid comprising a nucleotide sequence encoding a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima, or encoding a homolog of the polypeptide, or a complement of the nucleic acid and a method of producing a recombinant 250 kDa polypeptide of the same. The present invention also provides an isolated nucleic acid comprising a nucleotide sequence encoding an immunodominant portion of a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima having the amino acid sequence described herein, or encoding a homolog of the polypeptide, or a complement of the nucleic acid.
Type:
Grant
Filed:
July 3, 2002
Date of Patent:
December 9, 2008
Assignees:
University of Technology, Sydney, Abic Biological Laboratories Teva, Ltd.
Inventors:
David Witcombe, Nicholas C. Smith, Michael Wallach
Abstract: Expression cassettes are provided comprising a promoter operably linked to a nucleic acid molecule which, when transcribed in vivo, forms double-stranded RNA that induces the production of interferon. Expression cassettes also are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, forms a ribozyme or antisense RNA molecule that stimulates an immune response. In addition, expression cassettes are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, stimulates apoptosis. Finally, gene delivery vectors are provided which contain such expression cassettes, host cells containing the gene delivery vectors, and methods of utilizing the expression cassettes, gene delivery vectors, and host cells.
Type:
Application
Filed:
April 29, 2008
Publication date:
November 27, 2008
Inventors:
Thomas W. Dubensky, JR., John M. Polo, Barbara A. Belli, Silvia Perri, Timothy C. Fong
Abstract: A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor is provided. M-CSF induces DCs to differentiate into subtypes, for example plasmacytoid DCs and conventional DCs. Induction with M-CSF can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.
Abstract: The present invention provides a composition for suppressing an inflammatory immune response comprising the excretory/secretory (ES) component of Fasciola hepatica or a fraction thereof. The composition has particular utility in the treatment or prophylaxis of T cell mediated inflammatory immune responses, and in particular autoimmune disease. The invention further extends to methods for modulating a T cell mediated immune response wherein a therapeutically effective amount of the excretory/secretory (ES) component from Fasciola hepatica is administered to a subject in need of such treatment in order to suppress the development of the response.
Abstract: A novel Fasciclin Related Adhesive Protein (FRAP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. FRAP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, FRAP catalyzes the neutralization of heme by the parasite, by promoting its polymerization into hemozoin. This invention provides methods and compositions for therapies based on the administration of protein, DNA or cell-based vaccines and/or antibodies based on FRAP, or antigenic epitopes of FRAP, either alone or in combination with other parasite antigens. Methods for the development of compounds that inhibit the catalytic activity of FRAP, and diagnostic and laboratory methods utilizing FRAP are also provided.
Type:
Grant
Filed:
October 14, 2005
Date of Patent:
October 21, 2008
Assignee:
Virginia Tech Intellectual Properties, Inc.
Abstract: The present invention relates to an in vitro diagnostic method for malaria in an individual comprising placing a tissue or a biological fluid taken from an individual in contact with a molecule or polypeptide composition, wherein said molecule or polypeptide composition comprises one or more peptide sequences bearing all or part of one or more T epitopes of the proteins resulting from the infectious activity of P. falciparum, under conditions allowing an in vitro immunological reaction to occur between said composition and the antibodies that may be present in the tissue or biological fluid, and in vitro detection of the antigen-antibody complexes formed. The invention further relates to a polypeptide comprising at least one T epitope from a liver-stage specific protein produced by P. falciparum and a vaccine composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of P.
Type:
Grant
Filed:
April 17, 2006
Date of Patent:
October 21, 2008
Assignee:
Institut Pasteur
Inventors:
Claudine Guerin-Marchand, Pierre Druilhe
Abstract: The present invention provides the RSP-1 and RSP-2 proteins which are involved in the cytoadhesion of P. falciparum during ring-stage infection of erythrocytes, antibodies which bind to the proteins, methods of screening for a P. falciparum infection, methods of determining the infective stage of P. falciparum and vaccines for protecting individuals from Plasmodium sp. infections.
Type:
Grant
Filed:
November 29, 2002
Date of Patent:
October 7, 2008
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique
Inventors:
Juerg Gysin, Bruno Pouvelle, Artur Scherf, Pierre Buffet
Abstract: The present invention relates to nanoparticle vaccine adjuvants comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific site or cell type to optimize a desired immune response. The present invention also relates to encapsulating an antigen or combinations of different antigens within such nanoparticles, with or without a targeting molecule displayed on its surface. The antigens used in this invention are effective to produce an immune response against a variety of pathological conditions.
Type:
Application
Filed:
October 19, 2007
Publication date:
September 25, 2008
Inventors:
Jon O. Nagy, Benfang Lei, Zengshe Kevin Liu, Robert F. Bargatze, John W. Jutila, Jim E. Cutler, Pati M. Glee
Abstract: A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.
Abstract: The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins.
Type:
Grant
Filed:
July 3, 2002
Date of Patent:
September 9, 2008
Assignee:
Abic Biological Laboratories Teva, Ltd.
Inventors:
Sabina I. Belli, Nicholas C. Smith, Michael Wallach
Abstract: The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE.
Abstract: The present disclosure provides methods for enhancing the response of a patient's immune system to vaccination. This is accomplished by reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are delivered to increase the speed of regeneration of the patient's immune system. In one embodiment the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In one embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.
Abstract: A reagent and method for the specific and highly sensitive detection of C. parvum in which the reagent is an antibody for a soluble C. parvum sporozoite antigen and the method is an immunoassay in which the antibody is used to detect or quantify C. parvum sporozoite antigen in a sample. The sample is treated to cause excystation of C. parvum oocytes, thereby releasing a C. parvum sporozoite antigen, and combined with antibodies specific for the sporozoite antigen under conditions to form an antibody-antigen complex. Detection of the complex indicates the presence of C. parvum in the sample. The assay allows recognition and detection of C. parvum in turbid samples, and due to a lack of crossreactivity with other Cryptosporidium species, is specific for C. parvum contamination or infection. The assay is highly sensitive, allowing for the detection of less than 100 oocysts per milliliter of sample.
Type:
Grant
Filed:
April 14, 2006
Date of Patent:
August 12, 2008
Assignee:
The United States of America as represented by the Department of Health and Human Services, Center for Disease Control and Prevention
Inventors:
Victor C. W. Tsang, Jeffrey L. Call, Yeuk-mui Lee, Kathy Hancock